There are various tools used for the evaluation of chemotherapy-induced peripheral neuropathy namely the "Common Terminology Criteria for Adverse Events" (CTCAE) developed by the National Cancer Institute, the "European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire C30" (EORTC QLQ-C30), and the "Chemotherapy-Induced Peripheral Neuropathy-20 Questionnaire" (CIPN20).

Both nerve conduction studies and electromyography are expected to demonstrate symptoms of an axonopathy but are not performed routinely due to the costs involved. An indirect laryngoscopic examination in patients presenting with hoarseness of voice will likely demonstrate reduced mobility of the affected vocal cord.

SIADH is known to be present with symptoms of hypovolemic hyponatremia and may require determination of urine and plasma osmolarity for its diagnosis.

Hepatic veno-occlusive disease is expected to present with symptoms of jaundice, anasarca, weight gain, and decreased or absent blood flow in the hepatic vein on duplex ultrasonography.sine qua non in the diagnosis, whereas transfusion refractory thrombocytopenia is an addition in a recent modification of the diagnostic criteria.